A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Darbepoetin Alfa (ARANESP)

Erythropoiesis-stimulating Agent class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2006-06-07
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$185.36/unit
4 NDCs benchmarked, lowest of all strengths.
Average NADAC
$724.37
Across all dosage forms in distribution.
Highest NADAC
$1509.30
Wide spread — brand-strength NDCs still in market.
Plans with PA
780 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Darbepoetin Alfa used for?

Darbepoetin Alfa is a Erythropoiesis-stimulating Agent medication tracked in Medicare Part D.

Is there a generic for Darbepoetin Alfa?

No. Darbepoetin Alfa is brand-only with no generic equivalents currently in market.

How much does my plan pay for Darbepoetin Alfa?

Across 329 Part D plans, Darbepoetin Alfa averages $724.37/unit (NADAC). Lowest available: $185.36/unit. Highest in distribution: $1509.30/unit.

Is Darbepoetin Alfa on the FDA shortage list?

No. Darbepoetin Alfa is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file (4 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.